PharmaCyte Biotech, Inc.PMCBNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank74
3Y CAGR+60.1%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+60.1%/yr
vs -63.2%/yr prior
Acceleration
+123.3pp
Accelerating
Percentile
P74
Within normal range
vs 3Y Ago
4.1x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 48.27% |
| Q3 2025 | -24.92% |
| Q2 2025 | 7.22% |
| Q1 2025 | 21.26% |
| Q4 2024 | 1.51% |
| Q3 2024 | 1.95% |
| Q2 2024 | -25.68% |
| Q1 2024 | 54.49% |
| Q4 2023 | -21.49% |
| Q3 2023 | 21.67% |
| Q2 2023 | 89.18% |
| Q1 2023 | -74.50% |
| Q4 2022 | 11.76% |
| Q3 2022 | -37.31% |
| Q2 2022 | 60.76% |
| Q1 2022 | 16.88% |
| Q4 2021 | -5.84% |
| Q3 2021 | -55.16% |
| Q2 2021 | 83.97% |
| Q1 2021 | 15.05% |
| Q4 2020 | -44.08% |
| Q3 2020 | 177.07% |
| Q2 2020 | -13.81% |
| Q1 2020 | 531.53% |
| Q4 2019 | -75.20% |
| Q3 2019 | 301.54% |
| Q2 2019 | -69.54% |
| Q1 2019 | -48.62% |
| Q4 2018 | -57.02% |
| Q3 2018 | 6.22% |
| Q2 2018 | -68.59% |
| Q1 2018 | 55.70% |
| Q4 2017 | 20.53% |
| Q3 2017 | 146.12% |
| Q2 2017 | -70.03% |
| Q1 2017 | 128.44% |
| Q4 2016 | 45.01% |
| Q3 2016 | -26.34% |
| Q2 2016 | -58.61% |
| Q1 2016 | 30.54% |